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Introduction
Regional incidences of gastric cancer are variable, and the prev-
alence of the disease shows a declining tendency. However, gastric 
cancer remains the fourth most common malignancy worldwide, 
and there is a higher incidence of the disease in Far Eastern Asian 
countries, such as Korea and Japan.(1) This is in contrast to Western 
countries where the incidence is much lower. However, the West  
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has relatively higher proportions of UTG compared with Asian 
countries.(2) Some recent studies have reported an increasing trend 
in the incidence of UTG in Japan, China, and Korea.(3-6) The 2004 
Nationwide Gastric Cancer Registry also reported similar findings.
(7) Such increases could be related to recent changes in lifestyles of 
the Korean population. Some studies in both Western and Eastern 
countries have reported a poorer prognosis with UTG.(8,9) Others, 
however, found that the prognosis of patients with UTG was no 
poorer than that of patients with MLG in each equal TNM stage.
(10,11) It remains unclear whether the disease prognosis is due 
to different biologic characteristics or late detection. In this study, 
we evaluated chronological changes in the prevalence of UTG, 
the prognosis of UTG patients who underwent gastric resection at 




We retrospectively analyzed the medical records of 12,300 gastric 
cancer patients who underwent gastric resection between 1986 and 
2006 at SNUH. The location of the tumor was defined according to 
a Standardized Pathology Reports Guideline for Gastric Cancer in 
Korea.(12) Patients were grouped based on the presence of UTG or 
MLG. Patients who had received neoadjuvant chemotherapy or who 
had remnant or recurrent gastric cancer, synchronous gastric cancer, 
any other primary malignancy, or gastric cancer involving the entire 
stomach were excluded from the study. We evaluated numeric and 
proportional changes in UTG characteristics by linear regression. 
We compared patient demographic variables between groups, such as 
age and sex and surgical variables including type of operation, op-
erative radicalities, and survival rates. We also evaluated the status of 
lymph node metastasis, depth of tumor invasion, and TNM stage and 
assessed the tumors according to both the WHO’s and Lauren’s clas-
sifications. According to the WHO classification, the overall group 
was divided into an undifferentiated subgroup and a differentiated 
subgroup. The undifferentiated group included poorly differentiated 
cell types and signet ring cell types, and the differentiated group 
included well differentiated cell types and moderately differentiated 
cell types; papillary carcinoma and mucinous carcinoma were ex-
cluded from this subclassification.(13-15) To compare the prognosis, 
the 5-year survival rate was estimated in each group according to 
the TNM classification of the UICC 6th, and prognostic indica-
tors in all patients, including tumor locations, were evaluated by 
univariate and multivariate analysis.(16) Cross-table analysis with 
Chi-Square tests and Independent-samples T test with Levene’s 
test for equality of variances were used to compare each group, and 
missing values were excluded from statistical analysis in cell dif-
ferentiation and Lauren’s classification category, and the Kaplan-
Meier method was used to estimate the survival rates by perform-
ing a log-rank test. A Cox-proportional hazard model was used in 
the multivariate analysis. All tests were two-sided and performed at 
the 5% level of significance using SPSS Statistics 17.0 for Windows 
(SPSS Inc., Chicago, IL, USA).
Results
Among the 12,300 study group, 1,111 patients were excluded 
due to pre-operative chemotherapy (N=39), remnant gastric can-
Table 1. Clinicopathological characteristics of gastric cancer 









Age 54.7 55.8  0.002 
Sex (M : F) 2.0 : 1 2.1 : 1 0.425 
Operation method <0.001
    TG 1,108 (87.9%) 1,641 (16.5%)
    PG 149 (11.8%) 0 (0.0%)
    DSG 0 (0.0%) 8,218 (82.8%)
    Others* 3 (0.2%) 70 (0.7%)
Radicality 0.001 
    R0 1,152 (91.4%) 9,331 (94.0%)
    Non-R0 108 (8.6%) 598 (6.0%)
T stage
    EGC T1 282 (22.4%) 3,955 (39.8%)
<0.001
    AGC 978 (77.6%) 5,974 (60.2%)
T2a 134 (10.6%) 1,213 (12.2%)
T2b 437 (34.7%) 2,143 (21.6%)
T3 365 (29.0%) 2,499 (25.2%)
T4 42 (3.3%) 119 (1.2%)
N stage
    N0 531 (42.1%) 5,094 (51.3%)
<0.001
    N+ 729 (57.9%) 4,835 (48.7%)
N1 403 (32.0%) 2,618 (26.4%)
N2 211 (16.8%) 1,442 (14.5%)
N3 115 (9.1%) 775 (7.8%)
M stage
    M0 1,162 (92.2%) 9,411 (94.8%)
<0.001
    M1 98 (7.8%) 518 (5.2%)
TNM stage <0.001
    I 489 (38.8%) 5,070 (51.1%)
    II 274 (21.7%) 1,710 (17.2%)
    III 300 (23.8%) 1,960 (19.7%)
    IV 197 (15.6%) 1,189 (12.0%)
Mean tumor size (cm) 
    Overall stage 5.2  4.4  <0.001
    Stage I 3.5  3.2  0.020 
    Stage II 5.3  5.0  0.028 
    Stage III 6.5  5.8  <0.001
    Stage IV 7.7  6.9  0.182 
Resected LN (n) 31.3 ± 15.2  29.6 ± 13.9  <0.001
Invaded LN (n) 5.1  4.2  <0.001Jang JH, et al.
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cer (N=154), recurrent cancer (N=59), synchronous gastric cancers 
(N=457), synchronous other malignancy (N=55), gastric cancer 
involving the entire stomach (N=346), leaving a final study group 
of 11,189. The clinicopathological characteristics of these patients 
are shown in Table 1. The number of patients in the UTG group 
was 1,260 (11.3%), and the mean age was 54.7 years. The male to 
female ratio was about 2 : 1, which is not different from the MLG 
group. The proportion of patients with advanced gastric cancer was 
significantly higher in the UTG group compared with the MLG 
group (77.7% vs. 60.4%). Total gastrectomy was the most frequent 
type of operation performed in the UTG group; proximal gastrec-
tomy was performed in 11.8% of the patients. The proportion of 
R0 resection was slightly lower in the UTG group compared with 
the MLG group (91.4% vs. 94%). The distribution of the TNM 
stage showed more advanced stage cancer in UTG than in MLG 
patients, and the mean number of cancer-positive lymph nodes 
was greater in the UTG group. The mean tumor size in the UTG 
group was larger than that in the MLG group (5.2 cm vs. 4.4 cm). 
When TNM stages were compared, the UTG group showed a sig-
nificantly larger tumor size than the MLG group in all TNM stages 
except stage IV. There were some missing values in the cell differ-
entiation and Lauren’s classification categories due to limitations in 
medical records but the UTG group exhibited a significantly higher 
proportion of diffuse Lauren’s type and a higher proportion of un-
differentiated cell types compared to the MLG group (Table 1).
Chronologically, the proportion of UTG was 2.6% in 1986 










Diff  erentiated type
† 453 (36.9%) 4,511 (46.3%) <0.001
    Papillary 11 (0.9%) 45 (0.5%)
    WD 96 (7.7%) 1,393 (14.2%)
    MD 346 (27.9%) 3,073 (31.3%)
Undiff  erentiated type
† 773 (63.1%) 5,226 (53.7%)
    PD 572 (46.2%) 3,293 (33.5%)
    Mucinous 36 (2.9%) 456 (4.6%)
    Signet ring cell 165 (13.3%) 1,477 (15.0%)
Lauren’s classifi  cation
† <0.001
    Intestinal 398 (38.8%) 3,704 (47.4%)
    Diff  use 539 (52.5%) 5,322 (45.3%)
    Mixed 92 (8.9%) 549 (7.1%)
UTG = upper third gastric cancer; MLG = middle or lower third 
gastric cancer; TG = total gastrectomy; PG = proximal gastrectomy; 
DSG = distal subtotal gastrectomy; EGC = early gastric cancer; AGC = 
advanced gastric cancer; LN = lymph node; WD = well diff  erentiated; 
MD = moderately diff  erentiated; PD = poorly diff  erentiated. *Others 
= gastrojejunostomy (1), wedge resection (1), pylorus preserving 
gastrectomy (1) in UTG and gastrojejunostomy (16), wedge resection 
(12), pylorus preserving gastrectomy (40), exploration (2) in MLG; 
†The total number of subjects in cell differentiation and Lauren’s 
classification category is less than that stated enrolled number of 
patient due to missing value; 
‡P<0.05, statistically signifi  cant.
Fig. 1. Chronological changes in gastric cancer patient numbers based on tumor location. (A) Annual number of UTG and MLG at SNUH.  UTG 
was 2.6% (9 patients) in 1986 and rapidly increased to 12.5% (66 patients) in 1992. It reached a peak of 16.2% (96 patients) in 2004. A temporary 
drop in the rate to 12.5% (40 patients) was observed in 2000, which may be related to a medical strike at the time in Korea for separating medical 
practice and pharmaceutical dispensing system. (B) Estimated increase in the rates of UTG by linear regression analysis. Before 1992, UTG had 
been increasing at the rate of 1.69% per year (P<0.001, R
2=0.913); since 1992, the rate has reduced at 0.21% per year (P=0.028, R
2=0.321). UTG = 
upper third gastric cancer; MLG = middle or lower third gastric cancer; SNUH = Seoul National University Hospital.Upper Third Gastric Cancer
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Fig. 2. Chronological changes in gastric cancer stages based on the tumor location. Th   e proportion of stage I and II cancer increased in both groups, 
whereas the proportion of stage III and IV decreased; it is not clear whether this represents a real increase in the prevalence of EGC or is simply the 
result of greater diagnoses due to increased health screening. (A) Annual TNM stage distribution in UTG. (B) Annual TNM stage distribution in 
MLG. EGC = early gastric cancer; MLG = middle or lower third gastric cancer.
Fig. 3. Survival curve of gastric cancer in each stage based on the tumor locaton. Five-year survival rates in UTG were signifi  cantly lower compared 
with MLG in stage I, II, and III; there was no signifi  cant diff  erence in stage IV. (A) Stage I. (B) Stage II. (C) Stage III. (D) Stage IV. MLG = middle or 
lower third gastric cancer; UTG = upper third gastric cancer; YS = year survival rate. *P<0.05, statistically signifi  cant. Jang JH, et al.
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showed a slow increase, rising to 14.2% in 2006. The increase in 
the rate of UTG was estimated to be about 1.6% per year before 
1992 (P＜0.001); however, this dropped to 0.21% per year after 
1992 (P=0.028) (Fig. 1). The median age for UTG was in the sixth 
decade of life from 1986 to 1995. This shifted to the seventh decade 
of life after 1996, a finding that was also observed in the MLG 
group. A chronological review of the TNM stage showed that stage 
I and II cancers were more prevalent in both the UTG and MLG 
groups than in the past (Fig. 2). Comparison of the individual strat-
ified TNM stages showed that the 5-year survival rate of the UTG 
group was significantly poorer than that of the MLG in stage I-III 
(Fig. 3).
Tumor size, tumor location, Lauren’s classification, cell differ-
entiation, radicality, and TNM stage were identified as prognostic 
factors in univariate analysis. However, in multivariate analysis, sex, 
tumor size, tumor location, radicality, and TNM stage were found 
to be independent prognostic indicators (Table 2).
Discussion
The aim of this study was to evaluate chronological changes in 
the proportion of UTG during the past 21 years and to determine 
the prognosis of patients with UTG. In contrast to previous reports 
of an increasing trend in UTG worldwide, we found that the UTG 
proportions are nearly not changing these days. Prior to 1992, the 
prevalence of UTG showed a relatively rapid rise, with rates in-
creasing up to 1.69% annually. However, this rate has decreased 
to 0.21% per year since 1992 at SNUH (Fig. 1). Those changes 
are not likely the result in real incidence but may be attributable to 
increasing rates of screening for early gastric cancer (EGC); there 
was a simultaneous increase in the proportion of EGC identified 
during the same period. The changes may also be due to patient 
characteristics, with specific types of patients being referred to the 
SNUH. According to a nationwide survey of gastric cancer in Ko-
rea in 2004, the prevalence of UTG had increased from 11.2% to 
14.2%.(17) However, another nationwide survey of the disease in 
2009 reported a UTG prevalence of just 13.4% in Korea and con-
cluded that the increasing trend of UTG in Western countries has 
not been seen in Korea, a finding consistent with our study.(18) We 
observed a shift in the peak age distribution of UTG from the sixth 
to the seventh decade of life, which may be explained by the aging 
population in Korea. The decrease that we observed in TNM stage 
III and IV patients and the increase in stage I and II compared to 
the prevalence in the past could be attributable to technical ad-
vances in endoscopy and increased diagnosis of patients with early 
stage disease (Fig. 2). 
Table 2. Univariate analysis of prognostic factors in gastric cancer by Kaplan–Meier method and multivariate analysis according to Cox 
proportional hazards model. Size, TNM stage, radicality, and tumor location were analyzed for significant prognostic factors by both 









Sex Male vs. Female   0.459  1.199  1.096    1.312  <0.001
Age 40~59 vs. ~39   0.438  1.106  0.955    1.281    0.178 
60~ vs. ~39 <0.001 1.697  1.464    1.968  <0.001
Size (cm) 2~5 vs. <2 <0.001 1.239  1.069    1.437  0.004 
5< vs. <2 <0.001 1.540  1.319    1.798  <0.001
Cell diff  erentiation Undiff  erentiated vs. 
  Diff  erentiated
<0.001 1.066  0.941    1.208    0.316 
Lauren’s classifi  cation Diff  use vs. Intestinal <0.001 1.085  0.958    1.228    0.198 
TNM stage Stage II vs. I <0.001 2.717  2.375    3.108  <0.001
Stage III vs. I <0.001 5.401  4.766    6.122  <0.001
Stage IV vs. I <0.001 8.998  7.711  10.499  <0.001
Radicality Non-R0 vs. R0 <0.001 1.620  1.403    1.871  <0.001
Location UTG vs. MLG <0.001 1.230  1.099    1.377  <0.001
CI = confidence interval; UTG = Upper third gastric cancer; MLG = Middle or lower third gastric cancer. *Exp (B) = Hazard ratio; 
†P<0.05, 
statistically signifi  cant.Upper Third Gastric Cancer
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In the prognosis analysis, patients with UTG showed a poorer 
prognosis than those with MLG, with significantly lower 5-year 
survival rates in each TNM stage, except stage IV. The poor prog-
nosis with UTG compared with MLG may be due to a number of 
factors. There was significantly less EGC but higher numbers of 
advanced gastric cancer (AGC) in the UTG group compared with 
the MLG group; stage III and IV lesions were 39.4% and 31.7% 
in the UTG and MLG groups, respectively. A significantly larger 
mean tumor size in TNM stage I, II, and III, larger mean number 
of invaded lymph node, lesser operative R0 resection rates were 
observed in the UTG group (Table 1). In relation to lymph node 
metastasis, the main lymphatic channels could be different in each 
group, raising the possibility that the lymphatic system may be 
implicated in the poorer prognosis. Kunisaki et al.(11) previously 
reported that UTG metastases operating through the complex lym-
phatic systems such as lymphatic systems of the lower esophagus 
arising from the mediastinum, intraabdominal superior lymphatic 
systems to the pancreas, and retroperitoneal lymphatic systems 
from around the aorta all contribute to the prognosis of UTG. 
Thus, meticulous lymph node dissection is essential. An additional 
factor that may contribute to a poor prognosis according to Sasako 
et al.(19) is incomplete mediastinal lymph node dissection, which 
may occur due to technical difficulties from the abdominal ap-
proach. However, randomized controlled studies found no survival 
benefit with a thoracic approach for lower esophageal lymph node 
dissection; they also reported additional complications associated 
with this procedure. Unfortunately, we were unable to analyze any 
additional influence of either the lymphatic channels or lymph node 
dissection in patient prognoses due to limited data.
The anatomical nature of the upper third part of the stomach, 
which is somewhat different to the distal section, may also be im-
plicated in a poor prognosis. According to Piso et al.,(20) the fact 
that the serosa layer is incompletely formed in the upper third sec-
tion of the stomach may result in AGC (advanced gastric cancer) 
being more prevalent in UTG.
Thus, the poor prognosis of UTG may be related to various fac-
tors, such as stomach anatomy, very complex lymphatic systems, or 
technical difficulties during surgery. However, the tumor itself may 
also be different in UTG compared with MLG. In one analysis, 
UTG showed a significantly higher incidence of undifferentiated 
cell types than MLG, a finding consistent with other studies. Maeda 
et al.(21) reported that UTG had a more aggressive disease course 
and poorer prognosis due to undifferentiated or poorly differentiat-
ed cancer cells leading to advanced gastric cancer. In Lauren’s clas-
sifications, UTG showed a higher proportion of diffuse type cells, 
whereas MLG exhibited more intestinal type cells (Table 1), all of 
which may be related to the differences in the pathophysiology of 
UTG and MLG. KcColl et al.(22) proposed that at least two differ-
ent etiological mechanisms could underlie the prognosis in gastric 
cancer. One involved Helicobacter pylori infection or autoimmune 
atrophic gastritis in MLG; the other involved gastroesophageal 
reflux and nitric oxide production in saliva leading to the develop-
ment of intestinal metaplasia, neoplasm, and more undifferentiated 
tumor cells in UTG. Thus, the upper third stomach differs from 
the middle and lower third stomach not only in anatomy but also 
in cancer development mechanisms.(23,24) 
Many studies of UTG cite late detection as an important factor 
in the poor prognosis of the disease; the most common symptoms 
of UTG, such as weight loss and gastroesophageal reflux are usually 
very insidious and do not occur until the disease is at an advanced 
stage.(8,21,25) Some studies have argued that early detection can 
improve the prognosis if radical resection can be performed.(5,10,11) 
In our study, early stage UTG showed nearly a 90% 5-year survival 
rate, suggesting that more effort should be expended on the early 
detection and treatment of upper third gastric lesions. As noted 
previously by Yokoi et al.,(26) there are some limitations associ-
ated with UTG screening, such as the presence of trivial mucosal 
lesions, simple color changes, and technical difficulties. To ensure 
that UTG lesions are not overlooked, the endoscopist should pay 
special attention when examining lesions in the upper third stom-
ach. 
As this was a retrospective analysis and patients who did not 
undergo surgery because of advanced disease were not included, 
our study does not represent all the clinical aspects of UTG in 
Korea. However, from a surgical perspective, it may offer useful 
information. 
In conclusion, the prevalence of UTG showed a temporary 
increasing trend prior to the 1990s, with an annual rise of 1.69%. 
However, since then, the annual rate of increase has been just 0.21% 
at SNUH. The UTG group showed significantly poorer 5-year 
survival rates compared with the MLG group in each TNM stage 
except stage IV. Tumor size, tumor location, radicality, and TNM 
stage were independent prognostic indicators in both univariate and 
multivariate analysis. 
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